GLPG250117C17500
- 0.00
- 0.000.00%
Galapagos Newsroom
Morgan Stanley Maintains Galapagos(GLPG.US) With Hold Rating, Maintains Target Price $31
Kepler Capital Remains a Sell on Galapagos (0JXZ)
Cautious Hold Rating for Galapagos: Unproven Efficacy and Logistical Concerns in CD19 CAR-T Programs
Morgan Stanley Maintains Galapagos(GLPG.US) With Hold Rating, Maintains Target Price $31
Morgan Stanley Maintains Galapagos(GLPG.US) With Hold Rating, Maintains Target Price $31
Galapagos Downgraded to Reduce From Hold at Kepler Cheuvreux
Morgan Stanley Maintains Galapagos(GLPG.US) With Hold Rating, Maintains Target Price $31
Morgan Stanley Maintains Galapagos(GLPG.US) With Hold Rating, Maintains Target Price $31
Analysts' Opinions Are Mixed on These Healthcare Stocks: Haleon PLC Sponsored ADR (HLN), Insmed (INSM) and Galapagos (GLPG)
Morgan Stanley Maintains Galapagos(GLPG.US) With Hold Rating, Maintains Target Price $31
Morgan Stanley Maintains Galapagos(GLPG.US) With Hold Rating, Maintains Target Price $31
Galapagos Is Maintained at Sector Perform by RBC Capital
Galapagos Analyst Ratings
A Quick Look at Today's Ratings for Galapagos(GLPG.US), With a Forecast Between $26 to $31
Morgan Stanley Maintains Galapagos(GLPG.US) With Hold Rating, Maintains Target Price $32
Cautious Hold on Galapagos Amid Uncertain BD and R&D Risks
Analysts Conflicted on These Healthcare Names: Galapagos (GLPG) and Roche Holding AG (OtherRHHVF)
J.P. Morgan Maintains Galapagos(GLPG.US) With Hold Rating, Cuts Target Price to $32
Morgan Stanley Maintains Galapagos(GLPG.US) With Hold Rating, Maintains Target Price $32
Galapagos (0JXZ) Gets a Hold From Barclays